MIRA CEO Sells $1.29M in Stock, Receives Large Option Grant in Late Form 5 Disclosure
Summary
MIRA Pharmaceuticals' CEO and Chairman, Erez Aminov, reported a significant sale of $1.29 million in common stock and received a substantial grant of over 3.15 million options/RSUs, as disclosed in a late Form 5 filing.
Key Events
-
Significant Option/RSU Grant
Aminov received a grant of 3,155,170 stock options/RSUs on December 17, 2025, which vested immediately.
-
Option Exercises
Aminov exercised 613,595 stock options on October 16, 2025, immediately preceding the share sale.
-
Late Disclosure
These transactions from March, October, and December 2025 were reported in a Form 5 filed on February 17, 2026.
Analysis
This Form 5 filing discloses several significant insider transactions by MIRA Pharmaceuticals' CEO and Chairman, Erez Aminov, that occurred in 2025 but were reported late. The most impactful event is the sale of 613,595 shares of common stock for approximately $1.29 million in October 2025. This substantial disposition by a key executive, following the exercise of options, signals a reduction in direct ownership and could be interpreted as a move to realize gains or for liquidity. Concurrently, the CEO received a very large grant of 3,155,170 stock options/RSUs in December 2025, which vested immediately. While this constitutes significant compensation, the potential dilution from such a large grant (representing over 7% of the company's current market capitalization in potential shares) could be a concern for investors. The combination of a material insider sale and a substantial dilutive compensation package suggests a negative market impact.
At the time of this filing, MIRA was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.3M. The 52-week trading range was $0.73 to $2.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.